Baugh & Associates LLC Decreases Stock Position in Abbott Laboratories $ABT

Key Points

• Baugh & Associates LLC reduced its holdings in Abbott Laboratories by 5.1%, selling 2,903 shares, and now owns about 53,822 shares worth approximately $6,679,000.
• Abbott Laboratories reported $1.26 earnings per share for the last quarter, meeting expectations, with a revenue of $11.14 billion, which is a 7.4% increase year-over-year.
• The company declared a quarterly dividend of $0.59 per share, with a dividend yield of 1.7%, set to be paid on November 17th to stockholders of record on October 15th.

Baugh & Associates LLC reduced its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 5.1% in the second quarter, according to its most recent filing with the SEC. The fund owned 53,822 shares of the healthcare product maker's stock after selling 2,903 shares during the period. Abbott Laboratories makes up 3.5% of Baugh & Associates LLC's investment portfolio, making the stock its 10th biggest position. Baugh & Associates LLC's holdings in Abbott Laboratories were worth $6,679,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in ABT. Nuveen LLC bought a new stake in Abbott Laboratories in the first quarter worth $1,658,180,000. GAMMA Investing LLC lifted its stake in Abbott Laboratories by 15,420.4% in the first quarter. GAMMA Investing LLC now owns 5,102,648 shares of the healthcare product maker's stock worth $676,866,000 after purchasing an additional 5,069,771 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Abbott Laboratories by 29.2% in the first quarter. Goldman Sachs Group Inc. now owns 15,985,797 shares of the healthcare product maker's stock worth $2,120,516,000 after purchasing an additional 3,616,471 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Abbott Laboratories by 12.8% during the first quarter. Wellington Management Group LLP now owns 29,763,415 shares of the healthcare product maker's stock valued at $3,948,117,000 after acquiring an additional 3,371,113 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Abbott Laboratories by 12.8% in the first quarter. Massachusetts Financial Services Co. MA now owns 14,451,305 shares of the healthcare product maker's stock worth $1,916,966,000 after purchasing an additional 1,639,954 shares during the last quarter. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Stock Performance

Shares of NYSE ABT traded up $0.78 during midday trading on Monday, hitting $136.82. 4,837,007 shares of the company's stock traded hands, compared to its average volume of 6,659,060. The firm has a fifty day moving average of $130.47 and a 200 day moving average of $131.12. Abbott Laboratories has a 1 year low of $110.86 and a 1 year high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The stock has a market capitalization of $238.13 billion, a price-to-earnings ratio of 17.15, a price-to-earnings-growth ratio of 2.58 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The company had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. During the same period in the previous year, the business posted $1.14 earnings per share. The firm's quarterly revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be given a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a yield of 1.7%. Abbott Laboratories's dividend payout ratio (DPR) is presently 29.57%.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.46% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on ABT. Leerink Partners began coverage on Abbott Laboratories in a report on Monday, June 16th. They set a "market perform" rating and a $143.00 price target on the stock. William Blair upgraded Abbott Laboratories to a "strong-buy" rating in a report on Thursday, July 17th. Royal Bank Of Canada boosted their price target on Abbott Laboratories from $145.00 to $147.00 and gave the company an "outperform" rating in a report on Tuesday, July 15th. Evercore ISI boosted their price target on Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. Finally, Mizuho increased their price target on shares of Abbott Laboratories from $130.00 to $140.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 16th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $145.22.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.